MultiCell Announces Licensing Agreement Between BMS and Xenotech

MultiCell Technologies a leading supplier of immortalized non-tumorigenic human hepatocytes as pharmaceutical candidate optimization tools announced that its licensee, XenoTech, executed a three-year use and propagation agreement with pharmaceutical company Bristol-Myers Squibb. Financial terms were not disclosed. This contract, the first from a major U.S. pharmaceutical company, allows Bristol-Myers Squibb to grow and use MultiCell's immortalized Fa2N-4 hepatocytes for internal testing purposes.

()a href="http://biz.yahoo.com/bw/050523/235497.html?.v=1" target="_blank">Yahoo News